<a class="ci-mono font-sans text-ink no-underline hover:text-accent" href="/gene/EGFR">EGFR E746_A750del

Predictive

Supports Sensitivity Response

—

submitted

EID4208

EGFR E746_A750del mutation has been associated with sensitivity to first generation EGFR tyrosine kinase inhibitors, including erlotinib. In an in vitro study, PC9 cells (EGFR E746_A750del) demonstrat… (full text at CIViC)

PMID 24893891 · Cross et al., 2014 · Open in CIViC

Lung Adenocarcinoma3

EGFR E746_A750del

Lung Non-Small Cell Carcinoma17

Predictive

Supports Sensitivity Response

—

submitted

EID4205

In a Taiwanese stage IV lung adenocarcinoma patient with brain metastasis harboring EGFR E746_A750del mutation, EGFR E746_A750del was reported to be sensitive to erlotinib treatment. The patient was t… (full text at CIViC)

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
163343	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications	1	Tyrosine kinase inhibitor response; EGFR-related lung cancer; Lung adenocarcinoma; Neoplasm	germline/somatic	5	Aug 27, 2022	clinvar

Variation

Clinical significance

Review status

Stars

Conditions

Origin

Submitters

Last evaluated

Source

163343

Conflicting classifications of pathogenicity

criteria provided, conflicting classifications

Tyrosine kinase inhibitor response; EGFR-related lung cancer; Lung adenocarcinoma; Neoplasm

germline/somatic

Aug 27, 2022

clinvar

Lung Non-Small Cell Carcinoma17
EGFR E746_A750del	Afatinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID2515 In a phase 2b/3 study of 585 lung adenocarcinoma patients who had a previous round of EGFR-TKI treatment, archival material was available for 141 patients. EGFR mutational analysis revealed that 96 tu… (full text at CIViC) PMID 22452896 · Miller et al., 2012 · Open in CIViC	civic
EGFR E746_A750del	Afatinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID2516 A phase 3 study of 345 stage IIIB-IV lung adenocarcinoma patients, reported improved median progression free survival (13.6 months vs. 6.9 months, HR: 0.47, 95% CI: 0.34-0.65, P=0.001) in EGFR mutatio… (full text at CIViC) PMID 23816960 · Sequist et al., 2013 · Open in CIViC	civic
EGFR E746_A750del	Afatinib	Predictive	D	Supports Sensitivity Response	3	submitted	EID5946 HCC827 and PC9 NSCLC cell lines containing delE746_A750 mutation had growth inhibition IC50 with afatinib of 0.0010 and 0.0015 micro molar respectively. In comparison, NCI-H3255 EGFR L858R NSCLC cell … (full text at CIViC) PMID 24353160 · Yasuda et al., 2013 · Open in CIViC	civic
EGFR E746_A750del	Cetuximab	Predictive	D	Supports Sensitivity Response	—	submitted	EID4216 In an in vitro study, a HCC827 cell line expressing an EGFR exon 19 deletion mutation demonstrated sensitivity to cetuximab treatment, compared to A549, H460, H322 cell lines expressing wild-type EGFR… (full text at CIViC) PMID 27040853 · Kang et al., 2016 · Open in CIViC	civic
EGFR E746_A750del	Durvalumab	Predictive	D	Supports Sensitivity Response	—	submitted	EID2518 In an in vitro study using PC9 cells (EGFR exon 19 deletion), inhibition of cell viability was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. PC9 cells demonstrated an i… (full text at CIViC) PMID 24893891 · Cross et al., 2014 · Open in CIViC	civic
EGFR E746_A750del	Erlotinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4215 A study of five clinical trials reported that chemotherapy na�ve non-small cell lung cancer patients with EGFR sensitizing mutations (exon 19 deletion, L858R, L861Q, or G719X) treated with erlotinib o… (full text at CIViC) PMID 19671843 · Jackman et al., 2009 · Open in CIViC	civic
EGFR E746_A750del	Erlotinib	Predictive	D	Supports Sensitivity Response	—	submitted	EID4199 In an in vitro study, PC9 cells (EGFR E746_A750del) demonstrated increased sensitivity to erlotinib (IC50:28.0 nmol/L vs 692.0 nmol/L) compared to NCI-H2073 cells (EGFR wild-type). PMID 24893891 · Cross et al., 2014 · Open in CIViC	civic
EGFR E746_A750del	Erlotinib	Predictive	D	Supports Sensitivity Response	—	submitted	EID4202 In an in vitro study, a HCC827 cell line expressing EGFR E746_A750delELREA demonstrated increased sensitivity to erlotinib treatment compared to QG56 cells expressing EGFR wild-type. Sensitivity was d… (full text at CIViC) PMID 25853010 · Abourbeh et al., 2015 · Open in CIViC	civic
EGFR E746_A750del	Erlotinib	Predictive	D	Supports Sensitivity Response	—	submitted	EID4203 In an in vitro study, HCC827 and PC9 cell lines expressing EGFR E746_A750del demonstrated increased sensitivity to erlotinib treatment (IC50=0.017�M and 0.071�M, respectively), comparable to NCI-H3255… (full text at CIViC) PMID 24353160 · Yasuda et al., 2013 · Open in CIViC	civic
EGFR E746_A750del	Erlotinib	Predictive	D	Supports Sensitivity Response	—	submitted	EID4204 In an in vitro study, HCC827 cells expressing EGFR E746_A750del mutation were associated with sensitivity to erlotinib treatment. Sensitivity was determined by assessing cell density and ERK phosphory… (full text at CIViC) PMID 27612423 · Ray et al., 2016 · Open in CIViC	civic
EGFR E746_A750del	Erlotinib	Predictive	D	Supports Sensitivity Response	—	submitted	EID4642 In an in vitro study, a Ba/F3 cell line expressing EGFR L747_A750insP demonstrated increased sensitivity to erlotinib treatment (IC50=5nM), comparable to Ba/F3 cells expressing EGFR L858R (a known sen… (full text at CIViC) PMID 17877814 · de Gunst et al., 2007 · Open in CIViC	civic
EGFR E746_A750del	Erlotinib	Predictive	D	Supports Sensitivity Response	4	submitted	EID5945 HCC827 and PC9 NSCLC cell lines containing delE746_A750 mutation had growth inhibition IC50 with erlotinib of 0.017 and 0.071 micro molar respectively. In comparison, NCI-H3255 EGFR L858R NSCLC cell l… (full text at CIViC) PMID 24353160 · Yasuda et al., 2013 · Open in CIViC	civic
EGFR E746_A750del	Gefitinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID2510 In a phase 3 clinical trial of Japanese NSCLC patients with EGFR mutations (n=230), patients treated with gefitinib were associated with improved progression free survival (10.8 months vs 5.4 months, … (full text at CIViC) PMID 20573926 · Maemondo et al., 2010 · Open in CIViC	civic
EGFR E746_A750del	Gefitinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID2511 In a phase 3 clinical trial of Japanese NSCLC patients with EGFR mutations (n=177), patients treated with gefitinib were associated with improved progression free survival (9.2 months vs 6.3 months, H… (full text at CIViC) PMID 20022809 · Mitsudomi et al., 2010 · Open in CIViC	civic
EGFR E746_A750del	Gefitinib	Predictive	C	Supports Sensitivity Response	4	accepted	EID4198 Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen patients who had shown partial response or clinical improvement in response to gefitinib. Of 7 tumors w… (full text at CIViC) PMID 15329413 · Pao et al., 2004 · Open in CIViC	civic
EGFR E746_A750del	Gefitinib	Predictive	D	Supports Sensitivity Response	—	submitted	EID2514 In an in vitro study using PC9 cells (EGFR exon 19 deletion), inhibition of cell viability was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. PC9 cells demonstrated an i… (full text at CIViC) PMID 24893891 · Cross et al., 2014 · Open in CIViC	civic
EGFR E746_A750del	Gefitinib	Predictive	D	Supports Sensitivity Response	2	accepted	EID2625 In an in vitro study using PC9 cells (EGFR exon 19 deletion), inhibition of cell viability was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. PC9 cells demonstrated an i… (full text at CIViC) PMID 24893891 · Cross et al., 2014 · Open in CIViC	civic

EGFR E746_A750del

Afatinib

Predictive

Supports Sensitivity Response

—

submitted

EID2515

In a phase 2b/3 study of 585 lung adenocarcinoma patients who had a previous round of EGFR-TKI treatment, archival material was available for 141 patients. EGFR mutational analysis revealed that 96 tu… (full text at CIViC)

PMID 22452896 · Miller et al., 2012 · Open in CIViC

EGFR E746_A750del

Afatinib

Predictive

Supports Sensitivity Response

—

submitted

EID2516

A phase 3 study of 345 stage IIIB-IV lung adenocarcinoma patients, reported improved median progression free survival (13.6 months vs. 6.9 months, HR: 0.47, 95% CI: 0.34-0.65, P=0.001) in EGFR mutatio… (full text at CIViC)

PMID 23816960 · Sequist et al., 2013 · Open in CIViC

EGFR E746_A750del

Afatinib

Predictive

Supports Sensitivity Response

submitted

EID5946

HCC827 and PC9 NSCLC cell lines containing delE746_A750 mutation had growth inhibition IC50 with afatinib of 0.0010 and 0.0015 micro molar respectively. In comparison, NCI-H3255 EGFR L858R NSCLC cell … (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

EGFR E746_A750del

Cetuximab

Predictive

Supports Sensitivity Response

—

submitted

EID4216

In an in vitro study, a HCC827 cell line expressing an EGFR exon 19 deletion mutation demonstrated sensitivity to cetuximab treatment, compared to A549, H460, H322 cell lines expressing wild-type EGFR… (full text at CIViC)

PMID 27040853 · Kang et al., 2016 · Open in CIViC

EGFR E746_A750del

Durvalumab

Predictive

Supports Sensitivity Response

—

submitted

EID2518

In an in vitro study using PC9 cells (EGFR exon 19 deletion), inhibition of cell viability was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. PC9 cells demonstrated an i… (full text at CIViC)

PMID 24893891 · Cross et al., 2014 · Open in CIViC

EGFR E746_A750del

Predictive

Supports Sensitivity Response

—

submitted

EID4215

A study of five clinical trials reported that chemotherapy na�ve non-small cell lung cancer patients with EGFR sensitizing mutations (exon 19 deletion, L858R, L861Q, or G719X) treated with erlotinib o… (full text at CIViC)

PMID 19671843 · Jackman et al., 2009 · Open in CIViC

EGFR E746_A750del

Predictive

Supports Sensitivity Response

—

submitted

EID4199

In an in vitro study, PC9 cells (EGFR E746_A750del) demonstrated increased sensitivity to erlotinib (IC50:28.0 nmol/L vs 692.0 nmol/L) compared to NCI-H2073 cells (EGFR wild-type).

PMID 24893891 · Cross et al., 2014 · Open in CIViC

EGFR E746_A750del

Predictive

Supports Sensitivity Response

—

submitted

EID4202

In an in vitro study, a HCC827 cell line expressing EGFR E746_A750delELREA demonstrated increased sensitivity to erlotinib treatment compared to QG56 cells expressing EGFR wild-type. Sensitivity was d… (full text at CIViC)

PMID 25853010 · Abourbeh et al., 2015 · Open in CIViC

EGFR E746_A750del

Predictive

Supports Sensitivity Response

—

submitted

EID4203

In an in vitro study, HCC827 and PC9 cell lines expressing EGFR E746_A750del demonstrated increased sensitivity to erlotinib treatment (IC50=0.017�M and 0.071�M, respectively), comparable to NCI-H3255… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

EGFR E746_A750del

Predictive

Supports Sensitivity Response

—

submitted

EID4204

In an in vitro study, HCC827 cells expressing EGFR E746_A750del mutation were associated with sensitivity to erlotinib treatment. Sensitivity was determined by assessing cell density and ERK phosphory… (full text at CIViC)

PMID 27612423 · Ray et al., 2016 · Open in CIViC

EGFR E746_A750del

Predictive

Supports Sensitivity Response

—

submitted

EID4642

In an in vitro study, a Ba/F3 cell line expressing EGFR L747_A750insP demonstrated increased sensitivity to erlotinib treatment (IC50=5nM), comparable to Ba/F3 cells expressing EGFR L858R (a known sen… (full text at CIViC)

PMID 17877814 · de Gunst et al., 2007 · Open in CIViC

EGFR E746_A750del

Predictive

Supports Sensitivity Response

submitted

EID5945

HCC827 and PC9 NSCLC cell lines containing delE746_A750 mutation had growth inhibition IC50 with erlotinib of 0.017 and 0.071 micro molar respectively. In comparison, NCI-H3255 EGFR L858R NSCLC cell l… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

EGFR E746_A750del

Predictive

Supports Sensitivity Response

—

submitted

EID2510

In a phase 3 clinical trial of Japanese NSCLC patients with EGFR mutations (n=230), patients treated with gefitinib were associated with improved progression free survival (10.8 months vs 5.4 months, … (full text at CIViC)

PMID 20573926 · Maemondo et al., 2010 · Open in CIViC

EGFR E746_A750del

Predictive

Supports Sensitivity Response

—

submitted

EID2511

In a phase 3 clinical trial of Japanese NSCLC patients with EGFR mutations (n=177), patients treated with gefitinib were associated with improved progression free survival (9.2 months vs 6.3 months, H… (full text at CIViC)

PMID 20022809 · Mitsudomi et al., 2010 · Open in CIViC

EGFR E746_A750del

Predictive

Supports Sensitivity Response

accepted

EID4198

Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen patients who had shown partial response or clinical improvement in response to gefitinib. Of 7 tumors w… (full text at CIViC)

PMID 15329413 · Pao et al., 2004 · Open in CIViC

EGFR E746_A750del

Predictive

Supports Sensitivity Response

—

submitted

EID2514

PMID 24893891 · Cross et al., 2014 · Open in CIViC

EGFR E746_A750del

Predictive

Supports Sensitivity Response

accepted

EID2625

PMID 24893891 · Cross et al., 2014 · Open in CIViC

Minimally Invasive Lung Adenocarcinoma1

Minimally Invasive Lung Adenocarcinoma1
EGFR E746_A750del	Erlotinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID2513 EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to erlotinib in a phase II trial for bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma). One patient … (full text at CIViC) PMID 15329413 · Pao et al., 2004 · Open in CIViC	civic

EGFR E746_A750del

Predictive

Supports Sensitivity Response

accepted

EID2513

EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to erlotinib in a phase II trial for bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma). One patient … (full text at CIViC)

PMID 15329413 · Pao et al., 2004 · Open in CIViC